Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer
Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer
复制标题
DOI：
10.1200/jco.1999.17.1.168
复制
发表时间：
1999-01-01
影响因子：
45.3
通讯作者：
Coleman, CN
中科院分区：
文献类型：
--
作者：
D'Amico, AV;Whittington, R;Coleman, CN
目的：提供前列腺特异性抗原（PSA）在根治性前列腺切除术（RP）或外束放射治疗（RT）后无失败生存率的nomographic评估，用于PSA时代诊断为临床局限性疾病的男性。患者和方法：采用Cox回归多变量分析来确定预处理PSA水平、1992年美国癌症联合委员会（AJCC）临床分期和活检Gleason评分在预测1,654例Tlc男性患者治疗后PSA失效时间中的预后意义，其中2例前列腺癌采用RP或RT治疗。治疗前PSA、AJCC临床分期和活检Gleason评分是RP或rt患者治疗后PSA失败时间的独立预测因子（P < 0.0001）。2年PSA失败率来自Cox回归模型和95%置信区间的bootstrap估计，以按预处理PSA、AJCC临床分期、活检Gleason评分和局部治疗方式分层的nomogram形式呈现。结论：早期（小于或等于2年）PSA失效的高危男性（> 50%）可以根据所接受的局部治疗类型和作为局限性前列腺癌常规检查的一部分获得的临床信息来识别。选择这些男性进行评估辅助系统治疗和改进局部治疗的试验可能是合理的。[J]中国医学杂志（英文版）：17 -17。(C) 1999年由美国临床肿瘤学会出版。
Purpose: to present nomograms providing estimates of prostate-specific antigen (PSA) failure-free survival after radical prostatectomy (RP) or external-beam radiation therapy (RT) for men diagnosed during the PSA era with clinically localized disease.Patients and Methods: A Cox regression multivariable analysis was used to determine the prognostic significance of the pretreatment PSA level, 1992 American Joint Committee on Cancer (AJCC) clinical stage, and biopsy Gleason score in predicting the time to posttherapy PSA failure in 1,654 men with Tlc,2 prostate cancer managed with either RP or RT,Results: Pretherapy PSA, AJCC clinical stage, and biopsy Gleason score were independent predictors (P < .0001) of time to posttherapy PSA failure in patients managed with either RP or RT. Two-year PSA failure rates derived from the Cox regression model and bootstrap estimates of the 95% confidence intervals are presented in the format of a nomogram stratified by the pretreatment PSA, AJCC clinical stage, biopsy Gleason score, and local treatment modality.Conclusion: Men at high risk(> 50%) for early(less than or equal to 2 years) PSA Failure could be identified on the basis of the type of local therapy received and the clinical information obtained as part of the routine work-up for localized prostate cancer. Selection of these men for trials evaluating adjuvant systemic and improved local therapies may be justified.J Clin Oncol 17:168-172. (C) 1999 by American Society of Clinical Oncology.